Zydus Cadila gets approval from USFDA to market Cisatracurium Besylate Injection

02 Sep 2020 Evaluate

Zydus Cadila has received final approval from the US Food & Drug Administration (USFDA) to market Cisatracurium Besylate Injection USP (US RLD: Nimbex) in the strength of 20 mg (base)/10 mL (2 mg/mL) Multiple-Dose Vial. Cisatracurium Besylate is a nondepolarizing skeletal neuromuscular blocker for intravenous administration. The drug will be manufactured at Liva plant of Cadila Healthcare. The group now has 297 approvals and has so far filed over 390 ANDAs since the commencement of the filing process in FY 2003-04.

Cadila Healthcare is an India-based pharmaceutical company. The company's subsidiaries include Zydus Wellness, Liva Pharmaceuticals, Biochem Pharmaceutical Industries, Zydus Technologies, German Remedies, Dialforhealth India, Dialforhealth Unity and Dialforhealth Greencross, among others.

Zydus Lifesciences Share Price

997.45 12.70 (1.29%)
15-May-2024 16:01 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1528.20
Dr. Reddys Lab 5872.35
Cipla 1405.95
Zydus Lifesciences 997.45
Lupin 1638.40
View more..
© 2024 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt.Ltd.